News

In an interview with Targeted Oncology, Richard Anderson, PhD discussed how fertility is impacted by many lymphoma treatments, and what can be done to help preserve fertility in patients prior to treatment.

Michael R. Bishop, MD, discusses chimeric antigen receptor T cells therapy in non-Hodgkin lymphoma.

A subgroup analysis of the phase 3 COSMIC-311 study revealed no key differences in the survival and responses observed with cabozantinib based on the age of patients with RAI-refractory differentiated thyroid cancer.

Florida Cancer Specialists & Research Institute has expanded its molecular testing capabilities at its state-of-the-art Pathology Laboratory in Fort Myers and is providing patients with clinical next-generation sequencing.

Kamran A. Ahmed, MD, discusses the data leading up to the phase 1/2 study of radiotherapy followed by intrathecal trastuzumab and pertuzumab for the management of HER2-positive breast cancer with leptomeningeal disease and what impact the study may have on the community oncology space.

Further research is warranted after a phase 1 study found the agent has a good safety profile with clinical efficacy.

Evanthia Roussos Torres, MD, PhD, discusses the study design of the phase 1 trail evaluating entinostat, nivolumab, and ipilimumab in patients with locally advanced or metastatic HER2-negative breast cancer that cannot be removed by surgery.

In an interview with Targeted Oncology™, Michael Chuong, MD explained of the validity of the MRI-guided radiation technique for use in patients with pancreatic cancer, how it compares with CT-guided radiation, and how a shift toward MRI-guided radiation may impact patients with pancreatic cancer in the future.

New NCCN guidelines are available for oncologists on treating and counseling patients with small cell lung cancer.

The breakthrough therapy designation marks the agents seventh regulatory designation.

The ASSURE trial is actively recruiting patients with chronic lymphocytic leukemia to receive acalabrutinib in an investigation of its safety and efficacy.

Lyniate Corepoint was selected by Cancer Treatment Centers of American as its strategic interoperability solution to support rapid growth and ongoing innovation initiatives designed to put patients at the center of care.

In an interview with Targeted Oncology™: Jeffrey Miller, MD, discussed the use of NK cell destruction to boost IL-15 efficacy in refractory tumors.

Luhua Wang, MD, discussed the impact that the approval of the CAR T-cell therapy brexucabtagene autoleucel has had on mantle cell lymphoma.

In an interview with Targeted Oncology, Marshall Posner, MD, discusses the use of the HB-201 and HB-202 vaccines in patients with human papillomavirus 16- positive cancers.

A phase 2 study suggests that tipifarnib may be more beneficial for patients with CMML, MDS, or MPNs and RAS pathway mutations than the general population of patients with these disease.

Based on results from the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan has been granted another breakthrough therapy designation by the FDA.

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the differences between the global and Asian cohorts in the KAMILLA trial (NCT01702571), which evaluates the benefit of trastuzumab emtansine (T-DM1, Kadcyla) in patients with HER2-positive breast cancer who have received prior anti-HER2 and chemotherapy-based treatment.

In an interview with Targeted Oncology, Patrick Connor Johnson, MD, discussed the top considerations taken into account by physicians when choosing a third-line therapy for diffuse large B-cell lymphoma.

The FDA has approved brexucabtagene autoleucel for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Treatment with the investigational agent SY-2101 has begun in a phase 3 clinical trial of patients with newly-diagnosed acute promyelocytic leukemia.

Jason Westin, MD, discusses the current standard of care in diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Brad S. Kahl, MD, provided an efficacy update from the LOTUS-2 study and discussed multiple agents showing promise for the treatment of relapsed/refractory diffuse large B-cell lymphoma.

Axi-cel developer seeks to expand Axi-Cel for large B-cell lymphoma application to include the second-line setting.

In contrast to the innovations in cancer treatments that help drive improved survival, there are far fewer innovations targeting toxicities and providing supportive care.

Here is a look back FDA happenings from September 2021.

PARP inhibitors are a common treatment for ovarian cancer, but mechanisms of resistance have yet to be fully understood.

Positive findings from the phase 3 VISION have led the FDA to grant priority review to 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer.

NUC-1031, a drug for the first-line treatment of patients with advanced biliary tract cancer, has been granted fast track designation by the FDA.

lorida Cancer Specialists & Research Institute has announced the appointment of Michael Diaz, MD as President & Managing Physician.